Skip to main content
Mendus logo

Mendus — Investor Relations & Filings

Ticker · IMMU ISIN · SE0005003654 LEI · 529900AFBGFR7ZB50J95 ST Manufacturing
Open in API
Filings indexed 409 across all filing types
Latest filing 2026-05-27 Transaction in Own Shar…
Country SE Sweden
Listing ST IMMU

About Mendus

https://mendus.com/

Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.

Recent filings

Filing Released Lang Actions
Mendus AB (publ) has resolved to transfer own shares
Transaction in Own Shares Classification · 92% confidence The document is a press release announcing the board’s resolution to transfer up to 1,000,000 own shares on Nasdaq Stockholm under an existing AGM authorization. It provides details on the number of shares, transfer period, pricing interval, and reporting mechanism. This falls squarely under the category of transactions in own shares (share repurchase or disposal of treasury shares), which is code POS.
2026-05-27 English
Mendus AB (publ) har beslutat om överlåtelse av egna aktier
Transaction in Own Shares Classification · 90% confidence The document is a press release from Mendus AB announcing that the board, under authorization from the AGM, has decided to transfer (sell) up to 1,000,000 of its own (treasury) shares on Nasdaq Stockholm over a specified period. This is not an earnings release, financial report, AGM material, or other corporate action like dividend or merger. It specifically concerns the company’s own share transactions (selling treasury shares), which falls under “Transaction in Own Shares” (POS).
2026-05-27 Swedish
Report from the Annual General Meeting of Mendus AB (publ) on 8 May 2026
AGM Information Classification · 100% confidence The document is a detailed press release reporting on the resolutions and outcomes of the Annual General Meeting (AGM) of Mendus AB held on 8 May 2026. It includes adoption of financial statements, board member elections, remuneration decisions, share issuance authorizations, and incentive program approvals. The content is focused on the AGM proceedings and decisions rather than presenting a full annual report or financial statements themselves. The document explicitly references the AGM and its resolutions multiple times, and it is not a brief announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2026-05-08 English
Kommuniké från årsstämma i Mendus AB (publ) den 8 maj 2026
AGM Information Classification · 95% confidence The document is a press release dated May 8, 2026, reporting on the decisions made at the Annual General Meeting (Årsstämma) of Mendus AB. It includes details such as approval of financial statements, discharge of liability for the board and CEO, approval of the remuneration report, election and re-election of board members and auditors, decisions on board and auditor fees, authorization for share issuance and share transfers, and approval of a long-term incentive program. The content is typical of AGM minutes or a summary of AGM decisions rather than the full annual report or financial statements themselves. The document is about the meeting outcomes and resolutions passed at the AGM, not the full report or detailed financial data. Therefore, it fits the category of AGM Information (AGM-R). The document length (9293 characters) is consistent with a detailed AGM summary but not a full annual report. Hence, the classification is AGM Information (AGM-R) with high confidence.
2026-05-08 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled "Första kvartalsrapporten 2026" which translates to "First Quarterly Report 2026". It contains detailed financial data for the period January to March 2026, including net sales, results, earnings per share, cash, equity, and number of employees. It also includes a CEO statement, detailed descriptions of clinical programs, pipeline updates, and other operational information. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly indicate this is a comprehensive quarterly financial and operational report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Report on the first quarter 2026' and contains detailed financial data for the period January to March 2026, including net sales, results, earnings per share, cash, shareholders equity, and number of employees. It also includes a CEO comment, significant events during and after the reporting period, and detailed descriptions of clinical trials and company strategy. The content is comprehensive and covers financial performance and business developments for a quarter, which aligns with an Interim / Quarterly Report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or summary. There is no indication that this is an announcement of a report or a certification letter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.